Progress made during the elimination program
, the year of regional elimination initiative in Nepal, there has been decline in the kala-azar (VL) cases from 2,220/10,000 in 2003 to only 254 in 2017. However, in recent years, the region has witnessed an increase in the number of cases coming from previously nonendemic hilly regions [1, 2] . The cases of untreated post-kala-azar dermal leishmaniasis (PKDL) patients, a sequela of VL after treatment, has also increased; this potential reservoir of Leishmania creates concerns over the possibility of future epidemics [2] . Recent data, based upon sand fly feeding studies, suggests that disease transmission from PKDL cases is likely, with PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007616 September 19, 2019 1 / 5 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 feeding on nodular PKDL being more likely to result in positive xenodiagnoses than macular PKDL [3, 4] . In the ISC, 10%-15% of reportedly cured cases of VL develop PKDL. Modeling of cases reported indicates that achievement of elimination in low VL endemic areas will be difficult [5, 6] . Apart from PKDL as a reservoir, there are estimates of 5%-10% asymptomatic to symptomatic conversions per annum, adding a challenge to the elimination process [7, 8] ; the emergence of HIV-VL coinfection is another challenge [9] .
Issues with diagnosis
The rK39 dipstick test has been an essential diagnostic tool for VL over the past decade. However, as this test has variable sensitivity and limited use for PKDL and VL-HIV cases, novel tools are required. Overcoming the limitations of these diagnostic tests, further development and approval of nucleic acid amplification methods, such as the loop-mediated isothermal amplification (LAMP) assay [10, 11] and urine antigen detection using ELISA [12, 13] , are in the pipeline to provide a rapid and reliable diagnosis of VL and PKDL, capable of assessing the cure and monitoring the efficacy of new antileishmanial drugs. Adding additional challenge for sustained elimination, we also need a noninvasive antigen-based test that can be used for surveillance.
Drug treatment
Over the past decade, the use of oral miltefosine and single-course AmBisome (liposomal amphotericin B) since 2014 for VL have been the basis for the elimination program, although a comprehensive evaluation in their role in reducing patient numbers has not been made. Both treatments have limitations, with a 28-day regime and side effects, along with reported increase in miltefosine treatment failure [14] and the need for a cold-chain for AmBisome making additional demands, which have been supported by KalaCORE (a partnership to support the control and elimination of VL) and WHO. There also need to be follow-up studies to show whether the single course AmBisome regime is associated with higher PKDL incidence. These limitations have provided the rational for essential research on combination therapy and the identification of novel classes of chemical entities (e.g., oxoboroles, aminopyrazoles, and nitroimidazoles [15] . Currently efficacious combinations, using existing drugs, of miltefosineparomomycin or miltefosine-AmBisome are recommended in the region for VL. Combinations also offer hope for co-infections; in Ethiopia, AmBisome plus miltefosine have proved efficacious in HIV-VL patients [16] . Host-related therapies (for example, liposomal cholesterol) that have been effective in treatment of experimental VL model [17] deserve to be considered. To support studies on new treatments, we need much-improved serological, immunological, and genetic markers for clinical use that can determine progression from L. donovani infection to clinical VL. Markers for asymptomatic infections have been used in clinical studies [18, 19] . However, in the absence of specific safe drugs or markers of disease progression, studies on how to deal with these infections are needed.
Prevention using vaccination
With all the issues and adversities related to Leishmania treatment and management, prevention remains the key to sustainable elimination. Several vaccine strategies have been pursued using recombinant peptide, DNA, killed whole parasite and genetically modified live-attenuated parasites [20, 21] . Among them, L. donovani centrin gene knockout parasite has been reported to generate strong protective immune response in the animals against VL [22, 23] . Another promising centrin-deleted L. major vaccine candidate is currently being developed using marker-free CRISPR Cas9 technology. These parasites are safe and generate potent innate and adaptive protective immune response against both CL and VL. Currently, this vaccine candidate is being tested in dogs in endemic region and manufactured under good laboratory practice (GLP) and good manufacturing practice (GMP) conditions for future clinical trials. DNA and therapeutic vaccines are being actively developed by other laboratories. ChAd63-KH, an adenoviral vaccine encoding KMP-11 and HASPB, is currently in Phase II as a therapeutic vaccine for persistent PKDL in Sudan [24] . In addition, the new Phase IIa/b trial to assess whether ChAd63-KH as vaccine can avert the progression of VL to PKDL in previously treated VL patients will begin in Sudan soon. The process of technology transfer for manufacturing F3+/GLA-SE vaccine (LEISH-F3 recombinant protein antigen formulated with GLA-SE) against VL by Infectious Research Institute, Seattle, WA, USA after extensive antigen discovery and adjuvant development is in process [5] . Further preclinical development of a 5-antigen DNA vaccine [25] also continues.
Prevention through sand fly control
Although the elimination target in the ISC is currently defined as a public health problem, the accepted definitions of elimination [26, 27] are based upon the interruption of transmission. However, we do not have a proper measure of transmission of VL. As per a study in Bihar, no correlation was found between the presence of infected sand flies and the clinical VL occurrence [28] . Hence, further research is needed. Nevertheless, there are reports predicting the infected sand fly clusters to correlate to the disease burden in Nepal and Spain [29, 30] . The gaps in vector bionomics knowledge about leishmaniasis elimination include estimates of sand fly biting rates, parasite infection rates in the vector, and the spatial and temporal variations of these in response to indoor residual spraying (IRS) [31] . Addressing such knowledge gaps are of paramount importance to achieve sustained VL elimination within a policy focused on an appropriate post elimination program. The data on the poorly understood dispersal of the vector needs to be collected for better IRS. Because the sand fly modified its mostly endophilic (living indoors) habitat from past to exophilic (life outdoors) now [32], special tools targeting the vector with the exophilic habitat may be needed along with IRS. Further to the outcomes of this discussion, we invite submission of articles or reviews to PLOS Neglected Tropical Diseases on the following:
Papers that elaborate on the innovations related to elimination and control of leishmaniasis
including VL, cutaneous leishmaniasis, and post-kala-azar leishmaniasis in the areas of current status, genomics and basic science, immunology, epidemiology, transmission, diagnostics, drugs, vaccines and data, and health systems.
Papers on vector control measures handled to control sand fly population to reduce transmission.
Through the suggestions and kind support of various stakeholders, we will continue in our efforts towards the sustained elimination of VL from the ISC and improved control in East Africa as a goal by continued networking, conducting meetings, monitoring progress, updating information via publications, including publications in PLOS Neglected Tropical Diseases, until we have the tools, the health system structure, and funding to ensure elimination of VL based upon sustainable interruption of transmission.
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